BridgeBio to Present Clinical Data on Infigratinib for Achondroplasia at ESPE 2026

BridgeBio Pharmaceutical will showcase new research on how oral Infigratinib impacts medical complications associated with achondroplasia at the European Society for Paediatric Endocrinology meeting.

2 Sept, 11:30 — 2 Sept, 11:30

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual2d ago

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 - Taiwan News

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 Taiwan News

Read full article →

BridgeBio to Present Clinical Data on Infigratinib for Achondroplasia at ESPE 2026

Sources

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 - Taiwan News

Related Stories

Haze Drives Unhealthy Air Quality Across Southeast Asian Cities

Experimental Heart Drug Fails Key Trial Milestone

6-week-old infant died of measles, Pennsylvania county coroner says - edition.cnn.com

Salmonella Outbreak Linked to Pumpkin Seeds Infects Over 80 in France